Notificação de acontecimentos adversos ou reclamações de qualidade
AZ Medical Global

Áreas Terapêuticas
Medicamentos
Recursos
Conectar

Login

Search Medical Information

Para pesquisar informação científica, deverá especificar pelo menos dois termos de pesquisa

Search Medical Information

European Hematology Association

June 12 - 15, 2025

Acalabrutinib
AZD0120
Surovatamig (AZD0486)

pdf

Efficacy of rituximab-bendamustine with or without acalabrutinib in patients with untreated, high-risk mantle cell lymphoma: An analysis of the phase 3 ECHO trial

pdf

Venetoclax-acalabrutinib for CLL patients relapsing after venetoclax-antiCD20 treatment: Highly effective and low toxicity. Interim analysis of HOVON 159/REVEAL phase 2 trial

pdf

Minimal residual disease with bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Results from the phase 3 ECHO trial

pdf

Measurable residual disease kinetics with fixed-duration acalabrutinib-venetoclax combinations in treatment-naive chronic lymphocytic leukemia: Data from the phase 3 AMPLIFY trial

pdf

Analysis of COVID-19 infections with fixed-duration acalabrutinib-venetoclax combinations in treatment-naive chronic lymphocytic leukemia in the phase 3 AMPLIFY trial

pdf

Real-world treatment patterns and outcomes among patients with treatment-naïve mantle cell lymphoma in the UK, Sweden, and France

pdf

Real-world treatment patterns and outcomes among patients with high-risk, treatment-naïve mantle cell lymphoma in the UK, Sweden, and France

pdf

Updated results of a phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma

pdf

Autologous B cell maturation antigen (BCMA) and CD19 dual targeting FasTCAR-T cells (GC012F/AZD0120) as first-line therapy for elderly patients with newly diagnosed multiple myeloma patients

pdf

Safety and efficacy of AZD0486 in adolescent and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia: Early results from the phase 1/2 SYRUS study

pdf

Safety and efficacy of AZD0486, a CD19xCD3 T-cell engager, in relapsed or refractory diffuse large B-cell lymphoma

Não encontra o que procura?

Contacte-nos

Encontre um Medical Healthcare Partner

Submeter uma questão

A informação incluída neste website é dirigida exclusivamente a profissionais de saúde.

©2024 AstraZeneca. Todos os direitos reservados. PT-19636

Aprovado a 12/2024.

Sobre o AZMedical

AstraZeneca Portugal

Inquérito de Satisfação

Política de Privacidade

Aviso Legal e Termos de Utilização

Notificação de acontecimentos adversos ou reclamações de qualidade

Política de Privacidade

Aviso Legal e Termos de Utilização